New insider activity at Precision BioSciences ( (DTIL) ) has taken place on March 28, 2025.
Director Geno Germano has made a significant investment in Precision BioSciences by purchasing 3,250 shares of the company’s stock, amounting to a total value of $17,225.
Recent Updates on DTIL stock
Precision BioSciences has reported significant advancements in its gene editing programs, particularly with its PBGENE-HBV program targeting chronic Hepatitis B. The company announced the FDA clearance of its Investigational New Drug application for PBGENE-HBV, marking a significant milestone in the gene editing space. This clearance allows the expansion of the ELIMINATE-B trial in the U.S., which is already enrolling patients in Moldova, Hong Kong, and New Zealand. The company’s recent Q4 earnings report showed a net income of $7.2 million, a notable improvement from the previous year’s loss, attributed to increased revenues from new licensing agreements. Despite a decrease in quarterly revenues due to the conclusion of the Prevail agreement and nearing completion of the Novartis Agreement, Precision BioSciences remains financially stable with a cash runway extending into the second half of 2026. Analysts have responded positively to the promising clinical data and the potential of ARCUS nucleases in treating diseases like Duchenne muscular dystrophy and chronic Hepatitis B, highlighting the company’s strategic positioning in these markets.
More about Precision BioSciences
YTD Price Performance: -3.41%
Average Trading Volume: 507,773
Technical Sentiment Signal: Buy
Current Market Cap: $35.75M